Benzinga's Top #PreMarket Losers

shares dipped 74.70 percent to $9.00 following Phase 3 trial failure. Chimerix announced in a press release that a Phase 3 study for its SUPPRESS of brincidofovir did not achieve a primary endpoint for the prevention of clinically significant cytomegalovirus infection through Week 24 after transplant.

shares declined 3.09 percent to $13.50. Crude oil futures dipped 2.78 percent to trade at $37.04 a barrel.

fell 2.45 percent to $47.40 in pre-market trading after dropping 0.90 percent on Thursday.

shares tumbled 2.14 percent to $32.00 in pre-market trading after slipping 1.45 percent on Thursday.

shares dipped 1.11 percent to $191.77 in pre-market trading after falling 1.32 percent on Thursday.